Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Journal of The American Academy of Dermatology Année : 2020

Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients

Fichier principal
Vignette du fichier
1-s2.0-S0190962220300499-main.pdf (426.57 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

pasteur-02547275 , version 1 (19-04-2020)

Licence

Identifiants

Citer

Maïa Delage, J.-P. Jais, T. Lam, H. Guet-Revillet, Marie-Noëlle Ungeheuer, et al.. Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients. Journal of The American Academy of Dermatology, 2020, ⟨10.1016/j.jaad.2020.01.007⟩. ⟨pasteur-02547275⟩
419 Consultations
589 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More